BM-MSCs and AT-MSCs induced a similar decrease in NK cell proliferation and cytokine secretion.
BM-MSCs show higher capacity than AT-MSCs to inhibit NK cell cytotoxic activity but the same susceptibility to NK cell lysis.
AT-MSCs are more potent in inhibiting DC differentiation than BM-MSCs, but both similarly reduced the ability of DCs to induce CD4+ T cell proliferation and cytokine production.
BM-MSCs and AT-MSCs induce a similar decrease in T cell proliferation and production of inflammatory cytokines after activation.
MSCs from different donors could exert different immunomodulatory potential on the same receptor.